Citations (78)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Alessio Nocentini, Clemente Capasso & Claudiu T. Supuran. (2021) Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017–present). Expert Opinion on Therapeutic Patents 31:10, pages 867-876.
Read now
Read now
Bradley N. Spatola, Alana G. Lerner, Clifford Wong, Tracy dela Cruz, Megan Welch, Wanchi Fung, Maria Kovalenko, Karolina Losenkova, Gennady G. Yegutkin, Courtney Beers, John Corbin & Vanessa B. Soros. (2020) Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism. mAbs 12:1.
Read now
Read now
Ghasem Ghalamfarsa, Mohammad Hossein Kazemi, Sahar Raoofi Mohseni, Ali Masjedi, Mohammad Hojjat-Farsangi, Gholamreza Azizi, Mehdi Yousefi & Farhad Jadidi-Niaragh. (2019) CD73 as a potential opportunity for cancer immunotherapy. Expert Opinion on Therapeutic Targets 23:2, pages 127-142.
Read now
Read now
Marta Tomczyk, Paulina Mierzejewska, Ewa M. Slominska & Ryszard T. Smolenski. (2018) The metabolism of ecto-5’-nucleotidase (CD73) inhibitor-α,β-methylene adenosine diphosphate in BALB/c mice. Nucleosides, Nucleotides & Nucleic Acids 37:12, pages 709-716.
Read now
Read now
Dipti Vijayan, Deborah S. Barkauskas, Kimberley Stannard, Erin Sult, Rebecca Buonpane, Kazuyoshi Takeda, Michele W. L. Teng, Kris Sachsenmeier, Carl Hay & Mark J. Smyth. (2017) Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases. OncoImmunology 6:5.
Read now
Read now
Luca Antonioli, Corrado Blandizzi, Fabio Malavasi, Davide Ferrari & György Haskó. (2016) Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment. OncoImmunology 5:9.
Read now
Read now
Carl M. Hay, Erin Sult, Qihui Huang, Kathy Mulgrew, Stacy R. Fuhrmann, Kelly A. McGlinchey, Scott A. Hammond, Raymond Rothstein, Jonathan Rios-Doria, Edmund Poon, Nick Holoweckyj, Nicholas M. Durham, Ching Ching Leow, Gundo Diedrich, Melissa Damschroder, Ronald Herbst, Robert E. Hollingsworth & Kris F. Sachsenmeier. (2016) Targeting CD73 in the tumor microenvironment with MEDI9447. OncoImmunology 5:8.
Read now
Read now
Articles from other publishers (71)
Claudiu T. Supuran & Clemente Capasso. 2024. Metalloenzymes. Metalloenzymes
283
292
.
Chenyue Zhang, Kai Wang & Haiyong Wang. (2023) Adenosine in cancer immunotherapy: Taking off on a new plane. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:6, pages 189005.
Crossref
Crossref
Timo Massold, Fady Ibrahim, Viola Niemann, Bodo Steckel, Katrin Becker, Jürgen Schrader, Johannes Stegbauer, Sebastian Temme, Maria Grandoch, Ulrich Flögel & Pascal Bouvain. (2023) CD73 deficiency does not aggravate angiotensin II-induced aortic inflammation in mice. Scientific Reports 13:1.
Crossref
Crossref
Katarina Mihajlovic, Marija Adzic Bukvic, Milorad Dragic, Mirko Scortichini, Kenneth A. Jacobson & Nadezda Nedeljkovic. (2023) Anti-inflammatory potency of novel ecto-5′-nucleotidase/CD73 inhibitors in astrocyte culture model of neuroinflammation. European Journal of Pharmacology 956, pages 175943.
Crossref
Crossref
Mingxue Zhang, Xiaoqin Dai, Yu Xiang, Linshen Xie, Minghan Sun & Jianyou Shi. (2023) Advances in CD73 inhibitors for immunotherapy: Antibodies, synthetic small molecule compounds, and natural compounds. European Journal of Medicinal Chemistry 258, pages 115546.
Crossref
Crossref
Niklas Bach, Riekje Winzer, Eva Tolosa, Walter Fiedler & Franziska Brauneck. (2023) The Clinical Significance of CD73 in Cancer. International Journal of Molecular Sciences 24:14, pages 11759.
Crossref
Crossref
Johanna Bendell, Patricia LoRusso, Michael Overman, Anne M. Noonan, Dong-Wan Kim, John H. Strickler, Sang-We Kim, Stephen Clarke, Thomas J. George, Peter S. Grimison, Minal Barve, Manik Amin, Jayesh Desai, Trisha Wise-Draper, Steven Eck, Yu Jiang, Anis A. Khan, Yuling Wu, Philip Martin, Zachary A. Cooper, Nairouz Elgeioushi, Nancy Mueller, Rakesh Kumar & Sandip Pravin Patel. (2023) First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunology, Immunotherapy 72:7, pages 2443-2458.
Crossref
Crossref
Zainab Fatima, Abdulrahman Abonofal & Bettzy Stephen. (2023) Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors. Journal of Immunotherapy and Precision Oncology 6:2, pages 91-102.
Crossref
Crossref
Dong-Wan Kim, Sang-We Kim, D. Ross Camidge, Catherine A. Shu, Kristen A. Marrone, Xiuning Le, Collin M. Blakely, Keunchil Park, Gee-Chen Chang, Sandip Pravin Patel, Gozde Kar, Zachary A. Cooper, Ramin Samadani, Michael Pluta, Rakesh Kumar & Suresh Ramalingam. (2023) CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. Journal of Thoracic Oncology 18:5, pages 650-656.
Crossref
Crossref
Rayane Ghoteimi, Abdennour Braka, Céline Rodriguez, Emeline Cros‐Perrial, Valentin Duvauchelle, Jean‐Pierre Uttaro, Christophe Mathé, Christine Ménétrier‐Caux, Lars Petter Jordheim, Laurent Chaloin & Suzanne Peyrottes. (2023) Second‐Generation CD73 Inhibitors Based on a 4,6‐Biaryl‐2‐thiopyridine Scaffold. ChemMedChem 18:7.
Crossref
Crossref
Ryan R. Kowash & Esra A. Akbay. (2023) Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer. Frontiers in Immunology 14.
Crossref
Crossref
Ying Zhou, Haoran Shen, Min Wu, Jie Wang, Zhihai Wu, Fenggen Fu, Yang Liu, Jia Lu, Ying Yao, Nana Luo, Shuaixiang Zhou, Keai Sinn Tan, Bingliang Chen & Dongfang Wang. (2023) Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy. International Journal of Biological Macromolecules 229, pages 158-167.
Crossref
Crossref
Clemente Capasso, Alessio Nocentini & Claudiu T. Supuran. 2023.
Cabello Alemán Lucía. (2022) Future directions in cancer immunotherapy with monoclonal antibodies. Research Results in Pharmacology 8:4, pages 101-107.
Crossref
Crossref
Richard A Miller, Jason John Luke, Shenshen Hu, Suresh Mahabhashyam, William B Jones, Thomas Marron, Jaime R Merchan, Brett G M Hughes & Stephen B Willingham. (2022) Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. Journal for ImmunoTherapy of Cancer 10:12, pages e005802.
Crossref
Crossref
Shunsuke Kondo, Satoru Iwasa, Takafumi Koyama, Tomoko Fujita, Ko Sugibayashi, Kosho Murayama & Noboru Yamamoto. (2022) Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study. International Journal of Clinical Oncology 27:12, pages 1795-1804.
Crossref
Crossref
Roy S. Herbst, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy Chu, Isabelle Monnet, Alfredo Sanchez-Hernandez, Shaker Dakhil, D. Ross Camidge, Leanne Winzer, Yee Soo-Hoo, Zachary A. Cooper, Rakesh Kumar, John Bothos, Charu Aggarwal & Alex Martinez-Marti. (2022) COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology 40:29, pages 3383-3393.
Crossref
Crossref
Odd L Gammelgaard, Mikkel G Terp, Christian Renn, Aran F Labrijn, Oliver Hamaker, Aaraby Y Nielsen, Henriette Vever, Soren WK Hansen, Morten F Gjerstorff, Christa E Müller, Paul WHI Parren & Henrik J Ditzel. (2022) Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity. Journal for ImmunoTherapy of Cancer 10:9, pages e004554.
Crossref
Crossref
Yun Xing, Zhi-qiang Ren, Rui Jin, Liang Liu, Jin-peng Pei & Ker Yu. (2022) Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer. Acta Pharmacologica Sinica 43:9, pages 2410-2418.
Crossref
Crossref
Sunghyun Kang, Hwan-Woo Park & Kyung Ho Han. (2022) Antibodies Regulate Dual-Function Enzyme IYD to Induce Functional Synergy between Metabolism and Thermogenesis. International Journal of Molecular Sciences 23:14, pages 7834.
Crossref
Crossref
Andrea M Chambers, Kyle B Lupo, Jiao Wang, Jingming Cao, Sagar Utturkar, Nadia Lanman, Victor Bernal-Crespo, Shadia Jalal, Sharon R Pine, Sandra Torregrosa-Allen, Bennett D Elzey & Sandro Matosevic. (2022) Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors. eLife 11.
Crossref
Crossref
Yumin Han, Trevor Lee, Yongfeng He, Renuka Raman, Adriana Irizarry, M. Laura Martin & Giuseppe Giaccone. (2022) The regulation of CD73 in non-small cell lung cancer. European Journal of Cancer 170, pages 91-102.
Crossref
Crossref
Markus Kellner, Bettina von Neubeck, Bastian Czogalla, Regina Feederle, Binje Vick, Irmela Jeremias & Reinhard Zeidler. (2022) A Novel Anti-CD73 Antibody That Selectively Inhibits Membrane CD73 Shows Antitumor Activity and Induces Tumor Immune Escape. Biomedicines 10:4, pages 825.
Crossref
Crossref
McLane J. Watson & Greg M. Delgoffe. (2022) Fighting in a wasteland: deleterious metabolites and antitumor immunity. Journal of Clinical Investigation 132:2.
Crossref
Crossref
Melanie Wurm, Otmar Schaaf, Katharina Reutner, Rajkumar Ganesan, Sven Mostböck, Christina Pelster, Jark Böttcher, Bruna de Andrade Pereira, Christina Taubert, Isabella Alt, Garazi Serna, Aurelie Auguste, Kai B. Stadermann, Denis Delic, Fei Han, Jaume Capdevila, Paolo G. Nuciforo, Rachel Kroe-Barrett, Paul J. Adam, Anne B. Vogt & Irmgard Hofmann. (2021) A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway. Molecular Cancer Therapeutics 20:11, pages 2250-2261.
Crossref
Crossref
Georgina To'a Salazar, Ziyi Huang, Ningyan Zhang, Xue-Guang Zhang & Zhiqiang An. (2021) Antibody Therapies Targeting Complex Membrane Proteins. Engineering 7:11, pages 1541-1551.
Crossref
Crossref
Yen-Hao Chen, Hung-I Lu, Chien-Ming Lo & Shau-Hsuan Li. (2021) CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma. Cancers 13:16, pages 3982.
Crossref
Crossref
Rachel L. Palte, Veronica Juan, Yacob Gomez-Llorente, Marc Andre Bailly, Kalyan Chakravarthy, Xun Chen, Daniel Cipriano, Ghassan N. Fayad, Laurence Fayadat-Dilman, Symon Gathiaka, Heiko Greb, Brian Hall, Mas Handa, Mark Hsieh, Esther Kofman, Heping Lin, J. Richard Miller, Nhung Nguyen, Jennifer O’Neil, Hussam Shaheen, Eric Sterner, Corey Strickland, Angie Sun, Shane Taremi & Giovanna Scapin. (2021) Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action. Communications Biology 4:1.
Crossref
Crossref
Muhammad-Zawwad Raza, Octavia Cadassou, Charles Dumontet, Emeline Cros-Perrial & Lars Petter Jordheim. (2021) CD73 and cN-II regulate the cellular response to chemotherapeutic and hypoxic stress in lung adenocarcinoma cells. Biochimica et Biophysica Acta (BBA) - General Subjects 1865:5, pages 129842.
Crossref
Crossref
Alexey Churov & Galina Zhulai. (2021) Targeting adenosine and regulatory T cells in cancer immunotherapy. Human Immunology 82:4, pages 270-278.
Crossref
Crossref
Haofeng Sun, Lingyun Ma, Leyu Wang, Peng Xiao, Hongmei Li, Min Zhou & Dewei Song. (2021) Research advances in hydrogen–deuterium exchange mass spectrometry for protein epitope mapping. Analytical and Bioanalytical Chemistry 413:9, pages 2345-2359.
Crossref
Crossref
Sifan Lyu, Yunshuo Zhao, Xiao Zeng, Xiaotong Chen, Qingqing Meng, Zhe Ding, Wenshan Zhao, Yuanming Qi, Yanfeng Gao & Jiangfeng Du. (2021) Identification of Phelligridin-Based Compounds as Novel Human CD73 Inhibitors. Journal of Chemical Information and Modeling 61:3, pages 1275-1286.
Crossref
Crossref
Herbert Zimmermann. (2020) Ectonucleoside triphosphate diphosphohydrolases and ecto-5′-nucleotidase in purinergic signaling: how the field developed and where we are now. Purinergic Signalling 17:1, pages 117-125.
Crossref
Crossref
Elizabeth A. ThompsonJonathan D. Powell. (2021) Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches. Annual Review of Medicine 72:1, pages 331-348.
Crossref
Crossref
Ralph Minter, Kris Sachsenmeier, Zachary A. Cooper & Steven Rust. 2020. Phenotypic Drug Discovery. Phenotypic Drug Discovery
160
174
.
James E. Stefano, Dana M. Lord, Yanfeng Zhou, Julie Jaworski, Joern Hopke, Tara Travaline, Ningning Zhang, Karen Wong, Amanda Lennon, Timothy He, Eva Bric-Furlong, Cornishia Cherrie, Tristan Magnay, Elisabeth Remy, William Brondyk, Huawei Qiu & Katarina Radošević. (2020) A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms. Journal of Biological Chemistry 295:52, pages 18379-18389.
Crossref
Crossref
Jenna L. Jeffrey, Kenneth V. Lawson & Jay P. Powers. (2020) Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39. Journal of Medicinal Chemistry 63:22, pages 13444-13465.
Crossref
Crossref
Yan He, Yue Zhao, David M. Nelson, Anke Klippel & Michael D. Reily. (2020)
NMR-Based Assay for the
Ex Vivo
Determination of Soluble CD73 Activity in Serum
. Analytical Chemistry 92:21, pages 14501-14508.
Crossref
Crossref
Hilal Ahmed Parray, Shivangi Shukla, Sweety Samal, Tripti Shrivastava, Shubbir Ahmed, Chandresh Sharma & Rajesh Kumar. (2020) Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. International Immunopharmacology 85, pages 106639.
Crossref
Crossref
Meejeon Roh, Derek A Wainwright, Jennifer D Wu, Yong Wan & Bin Zhang. (2020) Targeting CD73 to augment cancer immunotherapy. Current Opinion in Pharmacology 53, pages 66-76.
Crossref
Crossref
Jiao Wang & Sandro Matosevic. (2020) Functional and metabolic targeting of natural killer cells to solid tumors. Cellular Oncology 43:4, pages 577-600.
Crossref
Crossref
Lucas G. Viviani, Erika Piccirillo, Henning Ulrich & Antonia T.-do Amaral. (2019) Virtual Screening Approach for the Identification of Hydroxamic Acids as Novel Human Ecto-5′-Nucleotidase Inhibitors. Journal of Chemical Information and Modeling 60:2, pages 621-630.
Crossref
Crossref
Siqi Chen, Jie Fan, Minghui Zhang, Lei Qin, Donye Dominguez, Alan Long, Gaoxiang Wang, Renqiang Ma, Huabin Li, Yi Zhang, Deyu Fang, Jeffrey Sosman & Bin Zhang. (2019) CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy. Nature Communications 10:1.
Crossref
Crossref
Said A. Goueli & Kevin Hsiao. (2019) Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39. PLOS ONE 14:10, pages e0220094.
Crossref
Crossref
Siqi Chen, Derek A Wainwright, Jennifer D Wu, Yong Wan, Daniela E Matei, Yi Zhang & Bin Zhang. (2019) CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy 11:11, pages 983-997.
Crossref
Crossref
Nadine S. Jahchan, Adriana M. Mujal, Joshua L. Pollack, Mikhail Binnewies, Venkataraman Sriram, Leonard Reyno & Matthew F. Krummel. (2019) Tuning the Tumor Myeloid Microenvironment to Fight Cancer. Frontiers in Immunology 10.
Crossref
Crossref
Selena Vigano, Dimitrios Alatzoglou, Melita Irving, Christine Ménétrier-Caux, Christophe Caux, Pedro Romero & George Coukos. (2019) Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. Frontiers in Immunology 10.
Crossref
Crossref
Nadezda Nedeljkovic. (2019) Complex regulation of ecto-5′-nucleotidase/CD73 and A2AR-mediated adenosine signaling at neurovascular unit: A link between acute and chronic neuroinflammation. Pharmacological Research 144, pages 99-115.
Crossref
Crossref
Salman Punekar & Daniel C. Cho. (2019) Novel Therapeutics Affecting Metabolic Pathways. American Society of Clinical Oncology Educational Book:39, pages e79-e87.
Crossref
Crossref
Ivan Perrot, Henri-Alexandre Michaud, Marc Giraudon-Paoli, Séverine Augier, Aurélie Docquier, Laurent Gros, Rachel Courtois, Cécile Déjou, Diana Jecko, Ondine Becquart, Hélène Rispaud-Blanc, Laurent Gauthier, Benjamin Rossi, Stéphanie Chanteux, Nicolas Gourdin, Beatrice Amigues, Alain Roussel, Armand Bensussan, Jean-François Eliaou, Jérémy Bastid, François Romagné, Yannis Morel, Emilie Narni-Mancinelli, Eric Vivier, Carine Paturel & Nathalie Bonnefoy. (2019) Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Reports 27:8, pages 2411-2425.e9.
Crossref
Crossref
Ryuma Tokunaga, Shu Cao, Madiha Naseem, Jae Ho Lo, Francesca Battaglin, Alberto Puccini, Martin D. Berger, Shivani Soni, Joshua Millstein, Wu Zhang, Sebastian Stintzing, Fotios Loupakis, Chiara Cremolini, Volker Heinemann, Alfredo Falcone & Heinz-Josef Lenz. (2019) Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. Clinical Colorectal Cancer 18:1, pages e8-e19.
Crossref
Crossref
Xin Chen, Xiaomin Song, Kang Li & Tong Zhang. (2019) FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. Frontiers in Immunology 10.
Crossref
Crossref
David Allard, Pavel Chrobak, Bertrand Allard, Nouredin Messaoudi & John Stagg. (2019) Targeting the CD73-adenosine axis in immuno-oncology. Immunology Letters 205, pages 31-39.
Crossref
Crossref
Silvana Morello, Roberta Turiello, Gabriele Madonna, Aldo Pinto, Paolo A. Ascierto & Mariaelena Capone. 2019. Tumor Immunology and Immunotherapy – Molecular Methods. Tumor Immunology and Immunotherapy – Molecular Methods
257
267
.
J. Posner, P. Barrington, T. Brier & A. Datta-Mannan. 2019. Concepts and Principles of Pharmacology. Concepts and Principles of Pharmacology
81
141
.
Charles Dumontet, Suzanne Peyrottes, Céline Rabeson, Emeline Cros-Perrial, Pierre Yves Géant, Laurent Chaloin & Lars Petter Jordheim. (2018) CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates. European Journal of Medicinal Chemistry 157, pages 1051-1055.
Crossref
Crossref
Nicolas Gourdin, Marion Bossennec, Céline Rodriguez, Selena Vigano, Christelle Machon, Camilla Jandus, David Bauché, Julien Faget, Isabelle Durand, Nicolas Chopin, Olivier Tredan, Julien C. Marie, Bertrand Dubois, Jérôme Guitton, Pedro Romero, Christophe Caux & Christine Ménétrier-Caux. (2018) Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints. Cancer Research 78:13, pages 3604-3618.
Crossref
Crossref
Bellamkonda K. Kishore, Simon C. Robson & Karen M. Dwyer. (2018) CD39-adenosinergic axis in renal pathophysiology and therapeutics. Purinergic Signalling 14:2, pages 109-120.
Crossref
Crossref
Theresa Kordaß, Wolfram Osen & Stefan B. Eichmüller. (2018) Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E. Frontiers in Immunology 9.
Crossref
Crossref
Stephan Menzel, Nicole Schwarz, Friedrich Haag & Friedrich Koch-Nolte. (2018) Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity. Frontiers in Pharmacology 9.
Crossref
Crossref
Marija Adzic & Nadezda Nedeljkovic. (2018) Unveiling the Role of Ecto-5′-Nucleotidase/CD73 in Astrocyte Migration by Using Pharmacological Tools. Frontiers in Pharmacology 9.
Crossref
Crossref
Yoshitomo Hamuro & Stephen J. Coales. (2018) Optimization of Feasibility Stage for Hydrogen/Deuterium Exchange Mass Spectrometry. Journal of the American Society for Mass Spectrometry 29:3, pages 623-629.
Crossref
Crossref
Rahila Rahimova, Simon Fontanel, Corinne Lionne, Lars Peter Jordheim, Suzanne Peyrottes & Laurent Chaloin. (2018) Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface. PLOS Computational Biology 14:1, pages e1005943.
Crossref
Crossref
N. DeVito, M. A. Morse, B. Hanks & J. M. Clarke. 2018. Early Phase Cancer Immunotherapy. Early Phase Cancer Immunotherapy
219
241
.
N. Bendriss-Vermare, N. Gourdin, N. Vey, J. Faget, V. Sisirak, I. Labidi-Galy, I. Le Mercier, N. Goutagny, I. Puisieux, C. Ménétrier-Caux & C. Caux. 2018. Oncoimmunology. Oncoimmunology
143
161
.
Silvana Morello, Mariaelena Capone, Claudia Sorrentino, Diana Giannarelli, Gabriele Madonna, Domenico Mallardo, Antonio M. Grimaldi, Aldo Pinto & Paolo Antonio Ascierto. (2017) Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. Journal of Translational Medicine 15:1.
Crossref
Crossref
Dipti Vijayan, Arabella Young, Michele W.L. Teng & Mark J. Smyth. (2017) Targeting immunosuppressive adenosine in cancer. Nature Reviews Cancer 17:12, pages 709-724.
Crossref
Crossref
Paola de Andrade Mello, Robson Coutinho-Silva & Luiz Eduardo Baggio Savio. (2017) Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives. Frontiers in Immunology 8.
Crossref
Crossref
Luca Antonioli, Sergey V. Novitskiy, Kris F. Sachsenmeier, Matteo Fornai, Corrado Blandizzi & György Haskó. (2017) Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discovery Today 22:11, pages 1686-1696.
Crossref
Crossref
M. Jack Borrok, Neil Mody, Xiaojun Lu, Megan L. Kuhn, Herren Wu, William F. Dall'Acqua & Ping Tsui. (2017) An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability. Journal of Pharmaceutical Sciences 106:4, pages 1008-1017.
Crossref
Crossref
Bertrand Allard, Maria Serena Longhi, Simon C. Robson & John Stagg. (2017) The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunological Reviews 276:1, pages 121-144.
Crossref
Crossref